Ayush medicines viz Ayush 64 and Kabasur Kudineer were administered to COVID-19 asymptomatic and mild to moderate patients during a campaign conducted by Ministry of Ayush.
A total of 63,265 patients were benefitted from these medicines. The outcomes of these interventions showed significant improvement in clinical recovery and duration of hospital stay without any progression of the disease to severe or critical stage, said in a press release issued by Press Information Bureau.
Also, there was improvement in Quality of life (QoL) parameters. This information was given by Minister of Ayush Sarbananda Sonowal in a written reply in Lok Sabha today.
All India Institute of Ayurveda
Further Mr Sonowal said the Ministry of Ayush, through its Autonomous Institute – All India Institute of Ayurveda (AIIA), New Delhi has signed a pact with London School of Hygiene & Tropical Medicine (LSH&TM), UK for conducting the study on “Ashwagandha for promoting recovery from Covid-19 in the UK” on July 22, 2021.
The study is a Randomized, placebo controlled double blind trial. The study was approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) and certified by WHO-GMP.
It is being conducted and monitored as per the internationally recognized GCP (Good Clinical Practices) guidelines.
AIIA has also signed an agreement with Frankfurter Innovations zentrum Biotechnologie GmbH (FIZ), Frankfurt, Germany on June15, 2021 for conducting Collaborative Research study entitled “Understanding the molecular mechanism of Guduchyadi tablets in combating COVID-19 infection- In-vitro & in-vivo study”.
Ministry of AYUSH and Ministry of Health and Family Welfare have jointly provided training to 33,000 AYUSH master trainers.
A total of 66,045 AYUSH Personnel had obtained training at igot.in platform on continual basis. Ministry of AYUSH has coordinated with Ministry of Health and Family Welfare for utilization of AYUSH manpower as COVID warrior for the management of Covid-19 with identified roles.